160 Health International Limited Achieves Major Milestone in Digital Healthcare Business Expansion

Key Highlights for Investors

• Significant Growth in Hospital Partnerships: 160 Health International Limited (“the Company” or “the Group”) has announced that, between January 2025 and March 31, 2026, the cumulative number of public medical institutions in operational collaboration with the Group has surged to 102 hospitals, up from 82 at the end of 2025.
• High-End Market Penetration: Of these, 54 are Class IIIA hospitals (the highest level in China’s hospital classification system), constituting approximately 52.9% of the total, and 78 are Class III or above, representing about 76.5%. This demonstrates strong traction and deep integration into the upper echelon of the Chinese medical system.
• Large Operational Scale: The partner hospitals collectively see an annual outpatient volume of approximately 84.37 million and generate annual revenue of around RMB99.7 billion. This underlines the Group’s access to a vast medical services network with significant revenue potential.
• Business Model Advancement: All partnerships are based on the innovative “160AI Hospital” operational collaboration model, which has transitioned from pilot projects to large-scale adoption.
• Strategic Technological Deployment: The Group is accelerating the roll-out of its “Medical Digital Staff” system, aiming for comprehensive AI-driven integration and smart healthcare transformation across its partner hospitals.

Detailed Analysis for Shareholders and Potential Investors

160 Health International Limited has made substantial progress in its core digital healthcare and wellness solutions business. The Company’s proprietary “160AI Hospital” operational collaboration model is now being implemented in a total of 102 public medical institutions, with a notable increase from 82 at the end of 2025. This expansion marks a further strengthening of the Company’s market position, particularly among high-tier hospitals. Of the 102 partner hospitals, 54 are Class IIIA hospitals (the highest classification), and 78 are Class III or above, indicating robust acceptance and successful penetration in China’s high-end healthcare sector.

The combined operational metrics of these partner institutions are impressive, with an estimated annual outpatient volume of 84.37 million and aggregate revenue reaching approximately RMB99.7 billion. These figures not only reflect the strong service capacity of the network but also highlight the Group’s potential to benefit from the ongoing digital transformation of healthcare services in China.

The “160AI Hospital” operational model is a core product for 160 Health International Limited, supporting the digitalization and AI-powered upgrade of hospital services. Having moved beyond the pilot stage, the model is now being deployed at scale, which is a key inflection point for the Group’s growth trajectory. This shift positions the Company as a leader in empowering public medical institutions with advanced digital and AI solutions.

Additionally, the Company is accelerating the deployment of its “Medical Digital Staff” system—an AI-driven solution designed to integrate multi-agent technology into medical workflows. This system aims to help hospitals transition to a new era of smart healthcare, enhancing efficiency and service quality through comprehensive digitalization.

Potential Price-Sensitive Information & Shareholder Considerations

• Expansion into High-Value Institutions: The rapid increase in Class IIIA and top-tier hospital partnerships could significantly expand the Company’s revenue base and operational influence in China’s healthcare sector.
• Large-Scale Adoption of AI Solutions: The successful scaling of the “160AI Hospital” model and “Medical Digital Staff” system could accelerate the Company’s growth and market valuation, given the market’s focus on digital health innovation.
• Market and Policy Risks: The Company explicitly cautions that the progress reported relates to specific business segments and may not reflect overall business performance. Future developments are subject to market, policy, and execution risks, which may impact the Company’s results and share price.

Management Statement

Mr. LUO Ningzheng, Chairman, Executive Director, and CEO, emphasized the Group’s ongoing commitment to expanding its national network of partner medical institutions, enhancing both the depth and breadth of its products and services, and driving high-quality growth in digital healthcare and wellness.

Board Composition

• Executive Directors: Mr. LUO Ningzheng, Mr. JI Cuilin, Mr. HUANG Lang, Mr. WANG Lifa
• Non-Executive Directors: Mr. LIU Haibin, Ms. SUN Meng
• Independent Non-Executive Directors: Mr. WANG Huan, Dr. XU Weiguo, Dr. FAN Ming

Conclusion

This announcement represents a potentially price-sensitive development for 160 Health International Limited, as it signals major progress in securing high-value partnerships, scaling AI-powered healthcare solutions, and expanding the Group’s market reach within China’s healthcare sector.

Disclaimer: The information above is based on the latest voluntary announcement from 160 Health International Limited as of April 21, 2026. Investors are reminded that the disclosed business progress pertains only to specific segments and may not represent the Company’s overall performance. Future results are subject to uncertainties including market conditions, regulatory changes, and execution risks. Please exercise caution in investment decisions.

View 160 HEALTH Historical chart here